Elliot A Asare1,2, Carolyn C Compton3, Nader N Hanna4, Lauren A Kosinski2, Mary Kay Washington5, Sanjay Kakar6, Martin R Weiser7, Michael J Overman8. 1. Cancer Programs, American College of Surgeons, Chicago, Illinois. 2. Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Department of Pathology, Arizona State University, Phoenix, Arizona. 4. Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland. 5. Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Department of Pathology, University of California at San Francisco Medical Center, San Francisco, California. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Department of Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Adenocarcinomas of the appendix represent a heterogeneous disease depending on the presence of mucinous histology, histologic grade, and stage. In the current study, the authors sought to explore the interplay of these factors with systemic chemotherapy in a large population data set. METHODS: Patients in the National Cancer Data Base (NCDB) who were diagnosed with mucinous, nonmucinous, and signet ring cell-type appendiceal neoplasms from 1985 through 2006 were selected. Multivariable Cox proportional hazards regression models were developed. RESULTS: A total of 11,871 patients met the inclusion criteria for the current study: 50.3% had mucinous neoplasms, 40.5% had nonmucinous neoplasms, and 9.2% had signet ring cell-type neoplasms. The 5-year overall survival (OS) stratified by grade was similar among patients with American Joint Committee on Cancer stage I to stage III disease but not for those with stage IV disease. The median OS for patients with stage IV mucinous and nonmucinous tumors was 6.4 years and 2.3 years, respectively, for those with well differentiated histology (P<.0001) and was 1.5 years and 0.8 years, respectively, for those with poorly differentiated histology (P<.0001). In multivariable modeling for stage I to III disease, adjuvant chemotherapy improved OS for both mucinous and nonmucinous histologies, with hazard ratios (HRs) of 0.78 (95% confidence interval [95% CI], 0.68-0.89 [P = .0002]) and 0.83 (95% CI, 0.74-0.94 [P = .002]), respectively. For patients with stage IV disease, systemic chemotherapy significantly improved OS for those with nonmucinous (HR, 0.72; 95% CI, 0.64-0.82 [P<.0001]) but not mucinous (HR, 0.95; 95% CI, 0.86-1.04 [P = .2) histologies, although this was grade-dependent. The median OS for chemotherapy versus no chemotherapy was 6.4 years versus 6.5 years (P value not significant) for patients with mucinous, well-differentiated tumors and 1.6 years versus 1.0 years (P = .0007) for patients with mucinous, poorly differentiated tumors. CONCLUSIONS: Adjuvant chemotherapy demonstrated a significant OS benefit regardless of histology. However, for patients with stage IV disease, the benefit of systemic chemotherapy varied by tumor histology and grade, with patients with well-differentiated, mucinous, appendiceal adenocarcinomas deriving no survival benefit from systemic chemotherapy. Cancer 2016;122:213-221.
BACKGROUND:Adenocarcinomas of the appendix represent a heterogeneous disease depending on the presence of mucinous histology, histologic grade, and stage. In the current study, the authors sought to explore the interplay of these factors with systemic chemotherapy in a large population data set. METHODS:Patients in the National Cancer Data Base (NCDB) who were diagnosed with mucinous, nonmucinous, and signet ring cell-type appendiceal neoplasms from 1985 through 2006 were selected. Multivariable Cox proportional hazards regression models were developed. RESULTS: A total of 11,871 patients met the inclusion criteria for the current study: 50.3% had mucinous neoplasms, 40.5% had nonmucinous neoplasms, and 9.2% had signet ring cell-type neoplasms. The 5-year overall survival (OS) stratified by grade was similar among patients with American Joint Committee on Cancer stage I to stage III disease but not for those with stage IV disease. The median OS for patients with stage IV mucinous and nonmucinous tumors was 6.4 years and 2.3 years, respectively, for those with well differentiated histology (P<.0001) and was 1.5 years and 0.8 years, respectively, for those with poorly differentiated histology (P<.0001). In multivariable modeling for stage I to III disease, adjuvant chemotherapy improved OS for both mucinous and nonmucinous histologies, with hazard ratios (HRs) of 0.78 (95% confidence interval [95% CI], 0.68-0.89 [P = .0002]) and 0.83 (95% CI, 0.74-0.94 [P = .002]), respectively. For patients with stage IV disease, systemic chemotherapy significantly improved OS for those with nonmucinous (HR, 0.72; 95% CI, 0.64-0.82 [P<.0001]) but not mucinous (HR, 0.95; 95% CI, 0.86-1.04 [P = .2) histologies, although this was grade-dependent. The median OS for chemotherapy versus no chemotherapy was 6.4 years versus 6.5 years (P value not significant) for patients with mucinous, well-differentiated tumors and 1.6 years versus 1.0 years (P = .0007) for patients with mucinous, poorly differentiated tumors. CONCLUSIONS: Adjuvant chemotherapy demonstrated a significant OS benefit regardless of histology. However, for patients with stage IV disease, the benefit of systemic chemotherapy varied by tumor histology and grade, with patients with well-differentiated, mucinous, appendiceal adenocarcinomas deriving no survival benefit from systemic chemotherapy. Cancer 2016;122:213-221.
Authors: C H Lieu; L A Lambert; R A Wolff; C Eng; N Zhang; S Wen; S Rafeeq; M Taggart; K Fournier; R Royal; P Mansfield; M J Overman Journal: Ann Oncol Date: 2011-06-08 Impact factor: 32.976
Authors: Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger Journal: Am J Surg Pathol Date: 2006-05 Impact factor: 6.394
Authors: Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young Journal: Am J Surg Pathol Date: 2003-08 Impact factor: 6.394
Authors: Xiaoying Liu; Kabir Mody; Francine B de Abreu; J Marc Pipas; Jason D Peterson; Torrey L Gallagher; Arief A Suriawinata; Gregory H Ripple; Kathryn C Hourdequin; Kerrington D Smith; Richard J Barth; Thomas A Colacchio; Michael J Tsapakos; Bassem I Zaki; Timothy B Gardner; Stuart R Gordon; Christopher I Amos; Wendy A Wells; Gregory J Tsongalis Journal: Clin Chem Date: 2014-05-12 Impact factor: 8.327
Authors: Melissa W Taggart; John Galbincea; Paul F Mansfield; Keith F Fournier; Richard E Royal; Michael J Overman; Asif Rashid; Susan C Abraham Journal: Am J Surg Pathol Date: 2013-08 Impact factor: 6.394
Authors: Hakan Alakus; Michele L Babicky; Pradipta Ghosh; Shawn Yost; Kristen Jepsen; Yang Dai; Angelo Arias; Michael L Samuels; Evangeline S Mose; Richard B Schwab; Michael R Peterson; Andrew M Lowy; Kelly A Frazer; Olivier Harismendy Journal: Genome Med Date: 2014-05-29 Impact factor: 11.117
Authors: Cecilia G Ethun; Lauren M Postlewait; Nina Le; Timothy M Pawlik; Stefan Buettner; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Nipun Merchant; Kenneth Cardona; Shishir K Maithel Journal: Ann Surg Oncol Date: 2016-11-03 Impact factor: 5.344
Authors: Celina S-P Ang; John Paul Shen; Camille J Hardy-Abeloos; Justin K Huang; Jeffrey S Ross; Vincent A Miller; Miriam T Jacobs; Ingrid L Chen; David Xu; Siraj M Ali; Joel Baumgartner; Andrew Lowy; Paul Fanta; Trey Ideker; Sherri Z Millis; Olivier Harismendy Journal: JCO Precis Oncol Date: 2018-08-08
Authors: Richard J Straker; Samuel Z Grinberg; Cimarron E Sharon; Adrienne B Shannon; Douglas L Fraker; Skandan Shanmugan; John T Miura; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2022-01-05 Impact factor: 5.344
Authors: L Martín Román; P Lozano; D Baratti; S Kusamura; M Deraco; W Vásquez; L González Bayón Journal: Ann Surg Oncol Date: 2022-07-25 Impact factor: 4.339
Authors: Kevin M Turner; Mackenzie C Morris; Aaron M Delman; Dennis Hanseman; Fabian M Johnston; Jonathan Greer; Kara Vande Walle; Daniel E Abbott; Mustafa Raoof; Travis E Grotz; Keith Fournier; Sean Dineen; Jula Veerapong; Ugwuji Maduekwe; Anai Kothari; Charles A Staley; Shishir K Maithel; Laura A Lambert; Alex C Kim; Jordan M Cloyd; Gregory C Wilson; Jeffrey J Sussman; Syed A Ahmad; Sameer H Patel Journal: J Gastrointest Surg Date: 2022-10-18 Impact factor: 3.267